Back to discover
Disease
Neurocognitive Disorders
Late-stage therapeutic developmentEmerging research
1
Publications
15
Clinical trials
1981
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Infantile autism reviewed: a decade of research.
Research1981-01-01Schizophrenia bulletin
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 3 clinical trials expected to report results, the earliest in Q4 2027.
Upcoming Milestones
- Q4 2027Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery (the INSPIRE Study)
- Q2 2028Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
- Q3 2028Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients: CODEX Trial
Major developments
Major trial resultsHigh impact
Results posted2026-06-18
Major trial resultsHigh impact
Results posted2026-06-29
Clinical MilestonesViewHide
Results posted
- 2026-06-29A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationResults posted
- 2026-06-18Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults With Early Symptomatic Alzheimer's DiseaseResults posted
Results expected
- 2026-06-03Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's DiseaseResults expected Q2 2028
- 2025-12-01Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients: CODEX TrialResults expected Q3 2028
- 2025-11-24Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery (the INSPIRE Study)Results expected Q4 2027
Recently completed
Activity timeline6
- 2026-06-29ClinicalA Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationResults posted
- 2026-06-18ClinicalInvestigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults With Early Symptomatic Alzheimer's DiseaseResults posted
- 2026-06-03ClinicalGlobal Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's DiseaseResults expected Q2 2028
- 2026-06-01ClinicalEfficacy and Safety of Oral Midazolam for the Delivery of Care in Elderly Patient With Moderate to Severe Neurocognitive Disorders and Refusing CarePrimary completion
- 2025-12-01ClinicalCognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients: CODEX TrialResults expected Q3 2028
- 2025-11-24ClinicalInterventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery (the INSPIRE Study)Results expected Q4 2027
Clinical trials
The current development programme across all trial phases.
Clinical programme
15
6
6
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Recent publications
Leading journals1
- Schizophrenia bulletin1
Leading researchers3
- DeMyer MK1
- Hingtgen JN1
- Jackson RK1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Diagnoses of DEMENTIA and AMNESTIC DISORDER are subsumed here. (DSM-5)
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.